nach oben

Erschienen in:

01.07.2014 | Original Contribution

β₃ adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes

verfasst von: Jaime García-Prieto, Jose Manuel García-Ruiz, David Sanz-Rosa, Andrés Pun, Ana García-Alvarez, Sean M. Davidson, Leticia Fernández-Friera, Mario Nuno-Ayala, Rodrigo Fernández-Jiménez, Juan A. Bernal, José Luis Izquierdo-Garcia, Jesús Jimenez-Borreguero, Gonzalo Pizarro, Jesús Ruiz-Cabello, Carlos Macaya, Valentín Fuster, Derek M. Yellon, Borja Ibanez

Erschienen in: Basic Research in Cardiology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Selective stimulation of β₃ adrenergic-receptor (β3AR) has been shown to reduce infarct size in a mouse model of myocardial ischemia/reperfusion. However, its functional long-term effect and the cardioprotective mechanisms at the level of cardiomyocytes have not been elucidated, and the impact of β3AR stimulation has not been evaluated in a more translational large animal model. This study aimed at evaluating pre-perfusion administration of BRL37344 both in small and large animal models of myocardial ischemia/reperfusion. Pre-reperfusion administration of the β3AR agonist BRL37344 (5 μg/kg) reduced infarct size at 2-and 24-h reperfusion in wild-type mice. Long-term (12-weeks) left ventricular (LV) function assessed by echocardiography and cardiac magnetic resonance (CMR) was significantly improved in β3AR agonist-treated mice. Incubation with β3AR agonist (BRL37344, 7 μmol/L) significantly reduced cell death in isolated adult mouse cardiomyocytes during hypoxia/reoxygenation and decreased susceptibility to deleterious opening of the mitochondrial permeability transition pore (mPTP), via a mechanism dependent on the Akt-NO signaling pathway. Pre-reperfusion BRL37344 administration had no effect on infarct size in cyclophilin-D KO mice, further implicating mPTP in the mechanism of protection. Large-white pigs underwent percutaneous coronary ischemia/reperfusion and 3-T CMR at 7 and 45 days post-infarction. Pre-perfusion administration of BRL37344 (5 μg/kg) decreased infarct size and improved long-term LV contractile function. A single-dose administration of β3AR agonist before reperfusion decreased infarct size and resulted in a consistent and long-term improvement in cardiac function, both in small and large animal models of myocardial ischemia/reperfusion. This protection appears to be executed through inhibition of mPTP opening in cardiomyocytes.

Nur mit Berechtigung zugänglich

Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt RF Jr, Arai AE (2006) Retrospective determination of the area at risk for reperfused acute myocardial infarction with t2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (dense) functional validations. Circulation 113:1865–1870. doi:10.1161/CIRCULATIONAHA.105.576025 PubMedCrossRef

Alzaga AG, Cerdan M, Varon J (2006) Therapeutic hypothermia. Resuscitation 70:369–380. doi:10.1016/j.resuscitation.2006.01.017 PubMedCrossRef

Aragon JP, Condit ME, Bhushan S, Predmore BL, Patel SS, Grinsfelder DB, Gundewar S, Jha S, Calvert JW, Barouch LA, Lavu M, Wright HM, Lefer DJ (2011) Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia–reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. J Am Coll Cardiol 58:2683–2691. doi:10.1016/j.jacc.2011.09.033 PubMedCentralPubMedCrossRef

Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD (2005) Loss of cyclophilin d reveals a critical role for mitochondrial permeability transition in cell death. Nature 434:658–662. doi:10.1038/nature03434 PubMedCrossRef

Bell R, Beeuwkes R, Botker HE, Davidson S, Downey J, Garcia-Dorado D, Hausenloy DJ, Heusch G, Ibanez B, Kitakaze M, Lecour S, Mentzer R, Miura T, Opie L, Ovize M, Ruiz-Meana M, Schulz R, Shannon R, Walker M, Vinten-Johansen J, Yellon D (2012) Trials, tribulations and speculation! Report from the 7th biennial hatter cardiovascular institute workshop. Basic Res Cardiol 107:300. doi:10.1007/s00395-012-0300-6 PubMedCrossRef

Bell RM, Kunuthur SP, Hendry C, Bruce-Hickman D, Davidson S, Yellon DM (2013) Matrix metalloproteinase inhibition protects cypd knockout mice independently of risk/mptp signalling: a parallel pathway to protection. Basic Res Cardiol 108:331. doi:10.1007/s00395-013-0331-7 PubMedCrossRef

Bhushan S, Kondo K, Predmore BL, Zlatopolsky M, King AL, Pearce C, Huang H, Tao YX, Condit ME, Lefer DJ (2012) Selective beta2-adrenoreceptor stimulation attenuates myocardial cell death and preserves cardiac function after ischemia–reperfusion injury. Arterioscler Thromb Vasc Biol 32:1865–1874. doi:10.1161/ATVBAHA.112.251769 PubMedCentralPubMedCrossRef

Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R (2010) Inhibition of permeability transition pore opening by mitochondrial stat3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 105:771–785. doi:10.1007/s00395-010-0124-1 PubMedCentralPubMedCrossRef

Bohl S, Medway DJ, Schulz-Menger J, Schneider JE, Neubauer S, Lygate CA (2009) Refined approach for quantification of in vivo ischemia–reperfusion injury in the mouse heart. Am J Physiol Heart Circ Physiol 297:H2054–2058. doi:10.1152/ajpheart.00836.2009 PubMedCentralPubMedCrossRef

10.

Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA (2004) Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95:125–134. doi:10.1161/01.RES.0000137171.97172.d7 PubMedCrossRef

11.

Botker HE, Kaltoft AK, Pedersen SF, Kim WY (2012) Measuring myocardial salvage. Cardiovasc Res 94:266–275. doi:10.1093/cvr/cvs081 PubMedCrossRef

12.

Bundgaard H, Liu CC, Garcia A, Hamilton EJ, Huang Y, Chia KK, Hunyor SN, Figtree GA, Rasmussen HH (2010) Beta(3) adrenergic stimulation of the cardiac na+–k+ pump by reversal of an inhibitory oxidative modification. Circulation 122:2699–2708. doi:10.1161/CIRCULATIONAHA.110.964619 PubMedCrossRef

13.

Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, Anderson JL, Yusuf S (2002) The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 39:30–36. doi:10.1016/S0735-1097(01)01711-9 PubMedCrossRef

14.

Calvert JW, Condit ME, Aragon JP, Nicholson CK, Moody BF, Hood RL, Sindler AL, Gundewar S, Seals DR, Barouch LA, Lefer DJ (2011) Exercise protects against myocardial ischemia–reperfusion injury via stimulation of beta(3)-adrenergic receptors and increased nitric oxide signaling: Role of nitrite and nitrosothiols. Circ Res 108:1448–1458. doi:10.1161/CIRCRESAHA.111.241117 PubMedCentralPubMedCrossRef

15.

Crompton M (1999) The mitochondrial permeability transition pore and its role in cell death. Biochem J 341(Pt 2):233–249. doi:10.1042/0264-6021:3410233 PubMedCentralPubMedCrossRef

16.

Cruz-Adalia A, Jimenez-Borreguero LJ, Ramirez-Huesca M, Chico-Calero I, Barreiro O, Lopez-Conesa E, Fresno M, Sanchez-Madrid F, Martin P (2010) Cd69 limits the severity of cardiomyopathy after autoimmune myocarditis. Circulation 122:1396–1404. doi:10.1161/CIRCULATIONAHA.110.952820 PubMedCrossRef

17.

Davidson SM, Hausenloy D, Duchen MR, Yellon DM (2006) Signalling via the reperfusion injury signalling kinase (risk) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 38:414–419. doi:10.1016/j.biocel.2005.09.017 PubMedCrossRef

18.

Davidson SM, Yellon DM, Murphy MP, Duchen MR (2012) Slow calcium waves and redox changes precede mitochondrial permeability transition pore opening in the intact heart during hypoxia and reoxygenation. Cardiovasc Res 93:445–453. doi:10.1093/cvr/cvr349 PubMedCrossRef

19.

Duchen MR, McGuinness O, Brown LA, Crompton M (1993) On the involvement of a cyclosporin a sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc Res 27:1790–1794. doi:10.1093/cvr/27.10.1790 PubMedCrossRef

20.

Eltzschig HK, Eckle T (2011) Ischemia and reperfusion—from mechanism to translation. Nat Med 17:1391–1401. doi:10.1038/nm.2507 PubMedCrossRef

21.

Frohlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ (2013) Myocardial reperfusion injury: looking beyond primary pci. Eur Heart J 34:1714–1722. doi:10.1093/eurheartj/eht090 PubMedCrossRef

22.

Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H (1996) Functional beta3-adrenoceptor in the human heart. J Clin Invest 98:556–562. doi:10.1172/JCI118823 PubMedCentralPubMedCrossRef

23.

Gerczuk PZ, Kloner RA (2012) An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol 59:969–978. doi:10.1016/j.jacc.2011.07.054 PubMedCrossRef

24.

Gomez L, Chavanis N, Argaud L, Chalabreysse L, Gateau-Roesch O, Ninet J, Ovize M (2005) Fas-independent mitochondrial damage triggers cardiomyocyte death after ischemia–reperfusion. Am J Physiol Heart Circ Physiol 289:H2153–2158. doi:10.1152/ajpheart.00165.2005 PubMedCrossRef

25.

Guo Y, Flaherty MP, Wu WJ, Tan W, Zhu X, Li Q, Bolli R (2012) Genetic background, gender, age, body temperature, and arterial blood ph have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: results of a comprehensive analysis of determinants of infarct size in 1,074 mice. Basic Res Cardiol 107:288. doi:10.1007/s00395-012-0288-y PubMedCentralPubMedCrossRef

26.

Hausenloy DJ, Baxter G, Bell R, Botker HE, Davidson SM, Downey J, Heusch G, Kitakaze M, Lecour S, Mentzer R, Mocanu MM, Ovize M, Schulz R, Shannon R, Walker M, Walkinshaw G, Yellon DM (2010) Translating novel strategies for cardioprotection: the hatter workshop recommendations. Basic Res Cardiol 105:677–686. doi:10.1007/s00395-010-0121-4 PubMedCentralPubMedCrossRef

27.

Hausenloy DJ, Yellon DM (2006) Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70:240–253. doi:10.1016/j.cardiores.2006.01.017 PubMedCrossRef

28.

Heusch G (2011) Beta3-adrenoceptor activation just says no to myocardial reperfusion injury. J Am Coll Cardiol 58:2692–2694. doi:10.1016/j.jacc.2011.09.034 PubMedCrossRef

29.

Heusch G (2013) Cardioprotection: chances and challenges of its translation to the clinic. Lancet 381:166–175. doi:10.1016/S0140-6736(12)60916-7 PubMedCrossRef

30.

Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118:1915–1919. doi:10.1161/CIRCULATIONAHA.108.805242 PubMedCrossRef

31.

Heusch G, Boengler K, Schulz R (2010) Inhibition of mitochondrial permeability transition pore opening: the holy grail of cardioprotection. Basic Res Cardiol 105:151–154. doi:10.1007/s00395-009-0080-9 PubMedCrossRef

32.

Heusch G, Skyschally A, Schulz R (2011) The in situ pig heart with regional ischemia/reperfusion—ready for translation. J Mol Cell Cardiol 50:951–963. doi:10.1016/j.yjmcc.2011.02.016 PubMedCrossRef

33.

Ibanez B, Cimmino G, Prat-Gonzalez S, Vilahur G, Hutter R, Garcia MJ, Fuster V, Sanz J, Badimon L, Badimon JJ (2011) The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion. Int J Cardiol 147:428–432. doi:10.1016/j.ijcard.2009.09.551 PubMedCentralPubMedCrossRef

34.

Ibanez B, Fuster V, Macaya C, Sanchez-Brunete V, Pizarro G, Lopez-Romero P, Mateos A, Jimenez-Borreguero J, Fernandez-Ortiz A, Sanz G, Fernandez-Friera L, Corral E, Barreiro MV, Ruiz-Mateos B, Goicolea J, Hernandez-Antolin R, Acebal C, Garcia-Rubira JC, Albarran A, Zamorano JL, Casado I, Valenciano J, Fernandez-Vazquez F, de la Torre JM, Perez de Prado A, Iglesias-Vazquez JA, Martinez-Tenorio P, Iniguez A (2012) Study design for the “effect of metoprolol in cardioprotection during an acute myocardial infarction” (metocard-cnic): A randomized, controlled parallel-group, observer-blinded clinical trial of early pre-reperfusion metoprolol administration in st-segment elevation myocardial infarction. Am Heart J 164(473–480):e475. doi:10.1016/j.ahj.2012.07.020

35.

Ibanez B, Prat-Gonzalez S, Speidl WS, Vilahur G, Pinero A, Cimmino G, Garcia MJ, Fuster V, Sanz J, Badimon JJ (2007) Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: Analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation 115:2909–2916. doi:10.1161/CIRCULATIONAHA.106.679639 PubMedCrossRef

36.

Ibarra C, Vicencio JM, Estrada M, Lin Y, Rocco P, Rebellato P, Munoz JP, Garcia-Prieto J, Quest AF, Chiong M, Davidson SM, Bulatovic I, Grinnemo KH, Larsson O, Szabadkai G, Uhlen P, Jaimovich E, Lavandero S (2013) Local control of nuclear calcium signaling in cardiac myocytes by perinuclear microdomains of sarcolemmal insulin-like growth factor 1 receptors. Circ Res 112:236–245. doi:10.1161/CIRCRESAHA.112.273839 PubMedCrossRef

37.

Kelley KW, Curtis SE, Marzan GT, Karara HM, Anderson CR (1973) Body surface area of female swine. J Anim Sci 36:927–930PubMed

38.

Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J Jr, Braunwald E (1971) Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43:67–82. doi:10.1161/01.CIR.43.1.67 PubMedCrossRef

39.

Niu X, Watts VL, Cingolani OH, Sivakumaran V, Leyton-Mange JS, Ellis CL, Miller KL, Vandegaer K, Bedja D, Gabrielson KL, Paolocci N, Kass DA, Barouch LA (2012) Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol 59:1979–1987. doi:10.1016/j.jacc.2011.12.046 PubMedCentralPubMedCrossRef

40.

Nowosielski M, Schocke M, Mayr A, Pedarnig K, Klug G, Kohler A, Bartel T, Muller S, Trieb T, Pachinger O, Metzler B (2009) Comparison of wall thickening and ejection fraction by cardiovascular magnetic resonance and echocardiography in acute myocardial infarction. J Cardiovasc Magn Reson 11:22. doi:10.1186/1532-429X-11-22 PubMedCentralPubMedCrossRef

41.

Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M (2008) Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359:473–481. doi:10.1056/NEJMoa071142 PubMedCrossRef

42.

Piper HM, Garcia-Dorado D, Ovize M (1998) A fresh look at reperfusion injury. Cardiovasc Res 38:291–300. doi:10.1016/S0008-6363(98)00033-9 PubMedCrossRef

43.

Rengo G, Zincarelli C, Femminella GD, Liccardo D, Pagano G, de Lucia C, Altobelli GG, Cimini V, Ruggiero D, Perrone-Filardi P, Gao E, Ferrara N, Lymperopoulos A, Koch WJ, Leosco D (2012) Myocardial beta(2)-adrenoceptor gene delivery promotes coordinated cardiac adaptive remodelling and angiogenesis in heart failure. Br J Pharmacol 166:2348–2361. doi:10.1111/j.1476-5381.2012.01954.x PubMedCentralPubMedCrossRef

44.

Sambrano GR, Fraser I, Han H, Ni Y, O’Connell T, Yan Z, Stull JT (2002) Navigating the signalling network in mouse cardiac myocytes. Nature 420:712–714. doi:10.1038/nature01306 PubMedCrossRef

45.

Schuster A, Kutty S, Padiyath A, Parish V, Gribben P, Danford DA, Makowski MR, Bigalke B, Beerbaum P, Nagel E (2011) Cardiovascular magnetic resonance myocardial feature tracking detects quantitative wall motion during dobutamine stress. J Cardiovasc Magn Reson 13:58. doi:10.1186/1532-429X-13-58 PubMedCentralPubMedCrossRef

46.

Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, Downey J, Gibbons RJ, Gottlieb RA, Heusch G, Jennings RB, Lefer DJ, Mentzer RM, Murphy E, Ovize M, Ping P, Przyklenk K, Sack MN, Vander Heide RS, Vinten-Johansen J, Yellon DM (2011) New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop. Circulation 124:1172–1179. doi:10.1161/CIRCULATIONAHA.111.032698 PubMedCrossRef

47.

Sharma V, Bell RM, Yellon DM (2012) Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy. Expert Opin Pharmacother 13:1153–1175. doi:10.1517/14656566.2012.685163 PubMedCrossRef

48.

Skyschally A, Schulz R, Heusch G (2010) Cyclosporine a at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 24:85–87. doi:10.1007/s10557-010-6219-y PubMedCentralPubMedCrossRef

49.

Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121–1135. doi:10.1056/NEJMra071667 PubMedCrossRef

50.

Zhou YY, Wang SQ, Zhu WZ, Chruscinski A, Kobilka BK, Ziman B, Wang S, Lakatta EG, Cheng H, Xiao RP (2000) Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. Am J Physiol Heart Circ Physiol 279:H429–H436PubMed

51.

Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ (2000) Reactive oxygen species (ros)-induced ros release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med 192:1001–1014. doi:10.1084/jem.192.7.1001 PubMedCentralPubMedCrossRef

Titel: β3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes
verfasst von: Jaime García-Prieto
Jose Manuel García-Ruiz
David Sanz-Rosa
Andrés Pun
Ana García-Alvarez
Sean M. Davidson
Leticia Fernández-Friera
Mario Nuno-Ayala
Rodrigo Fernández-Jiménez
Juan A. Bernal
José Luis Izquierdo-Garcia
Jesús Jimenez-Borreguero
Gonzalo Pizarro
Jesús Ruiz-Cabello
Carlos Macaya
Valentín Fuster
Derek M. Yellon
Borja Ibanez
Publikationsdatum: 01.07.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Basic Research in Cardiology / Ausgabe 4/2014
Print ISSN: 0300-8428
Elektronische ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-014-0422-0

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

β₃ adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes

Abstract

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Cell-specific and endothelium-dependent regulations of matrix metalloproteinase-2 in rat aorta

Hypoxic preconditioning protects rat hearts against ischemia–reperfusion injury via the arachidonate12-lipoxygenase/transient receptor potential vanilloid 1 pathway

Mitochondrial KATP channel involvement in angiotensin II-induced autophagy in vascular smooth muscle cells

Myocardial blood flow and its transit time, oxygen utilization, and efficiency of highly endurance-trained human heart

Overexpression of the muscle-specific protein, melusin, protects from cardiac ischemia/reperfusion injury

Selective inhibition of inositol hexakisphosphate kinases (IP6Ks) enhances mesenchymal stem cell engraftment and improves therapeutic efficacy for myocardial infarction

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie